- Home
- GOOD vs AQST Comparison
GOOD vs AQST Comparison
Compare GOOD & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOOD | AQST |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | United States |
| Employees | 72 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.9M | 504.0M |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | GOOD | AQST |
|---|---|---|
| Price | $12.33 | $4.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $12.50 | $9.00 |
| AVG Volume (30 Days) | 385.3K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 9.80% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | $10.37 | $10.08 |
| Revenue Next Year | $2.56 | $49.60 |
| P/E Ratio | $62.41 | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $10.33 | $2.22 |
| 52 Week High | $14.70 | $7.55 |
Technical Indicators
Market Signals| Indicator | GOOD | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 63.88 | 51.45 |
| Support Level | $12.09 | $3.70 |
| Resistance Level | $13.44 | $4.42 |
| Average True Range (ATR) | 0.22 | 0.15 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 97.54 | 58.97 |
Price Performance
Historical ComparisonAbout GOOD Gladstone Commercial Corporation Real Estate Investment Trust
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.